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Summary
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by pathological deposits of b-amyloid (Ab) in senile
plaques, intracellular neurofibrillary tangles (NFTs) comprising
hyperphosphorylated aggregated tau, synaptic dysfunction and
neuronal death. Substantial evidence indicates that disrupted
neuronal calcium homeostasis is an early event in AD that could
mediate synaptic dysfunction and neuronal toxicity. Sodium
calcium exchangers (NCXs) play important roles in regulating
intracellular calcium, and accumulating data suggests that
reduced NCX function, following aberrant proteolytic cleavage
of these exchangers, may contribute to neurodegeneration. Here,
we show that elevated calpain, but not caspase-3, activity is a
prominent feature of AD brain. In addition, we observe increased
calpain-mediated cleavage of NCX3, but not a related family
member NCX1, in AD brain relative to unaffected tissue and that
from other neurodegenerative conditions. Moreover, the extent
of NCX3 proteolysis correlated significantly with amounts of
Ab1–42. We also show that exposure of primary cortical neurons
to oligomeric Ab1–42 results in calpain-dependent cleavage of
NCX3, and we demonstrate that loss of NCX3 function is
associated with Ab toxicity. Our findings suggest that Ab
mediates calpain cleavage of NCX3 in AD brain and therefore
that reduced NCX3 activity could contribute to the sustained
increases in intraneuronal calcium concentrations that are
associated with synaptic and neuronal dysfunction in AD.
Key words: Alzheimer’s disease; beta-amyloid; calcium;
calpain; sodium calcium exchanger; tau.
Introduction
Degenerating brain regions in Alzheimer’s disease (AD) show deposits of
b-amyloid (Ab) in senile plaques and accumulation of hyperphosphory-
lated tau aggregates in intracellular neurofibrillary tangles (Schellenberg
& Montine, 2012). Substantial evidence indicates that disrupted neuronal
Ca2+ homeostasis in these brain areas is likely an early event in AD
pathogenesis that mediates synaptic dysfunction and neuronal toxicity
(Small, 2009; Li et al., 2011). However, the mechanisms leading to
prolonged elevations in intraneuronal Ca2+ ([Ca2+]i) in AD have yet to be
fully elucidated. Mutations in presenilin 1 (PS1) perturb [Ca2+]i, primarily
by inducing release of excess Ca2+ from the endoplasmic reticulum. Such
Ca2+ release occurs through a number of different mechanisms, including
alteration in ryanodine and inositol triphosphate receptor expression and
gating, and modified sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
function (Verkhratsky & Toescu, 2003). These events may account for
alterations in cellular Ca2+ homeostasis in familial AD. In cellular models
of sporadic AD, application of Ab has been shown to cause the formation
of Ca2+-permeable pores in bilayer membranes (Arispe et al., 1993)
or thinning of membranes resulting in increased ion permeability (Kayed
et al., 2004). Many reports also demonstrate that Ab stimulates neuronal
Ca2+ influx through native ion channels and/or receptors (Small, 2009),
and increased Ca2+ influx via these mechanisms leads to rapid increases
in neuronal Ca2+ content. Recent evidence has suggested that inactiva-
tion of plasma membrane ion exchangers may also contribute to
sustained neuronal Ca2+ overload in neurodegenerative conditions by
preventing the extrusion of excess cytosolic Ca2+ (Bano et al., 2005,
2007).
In conditions of high [Ca2+]i, the sodium calcium exchanger (NCX)
family members, NCX1, NCX2 and NCX3, activate high-capacity
currents to extrude excess Ca2+ from the cytosol in exchange for Na+
ions (Lytton, 2007). NCX3 is subject to cleavage by the Ca2+-activated
cysteine protease calpain-1 (Bano et al., 2005, 2007) and by caspase-3
(Bano et al., 2007).
Calpain-1-mediated cleavage of NCX3 diminishes NCX3 exchanger
activity by preventing the binding of Ca2+ to the NCX Ca2+ regulatory
domain, a process essential for NCX function (Bano et al., 2005, 2007).
In a cell-based model of ischaemia, Bano et al. (2005) found that
cleavage of NCX3 by calpain-1 caused the inactivation of NCX3 ionic
exchange activity, retention of intracellular Ca2+, prolonged calpain
activation and resultant neurotoxicity. These effects were reversed by
over-expression of the calpain inhibitor, calpastatin. Similar outcomes
have also been reported following the treatment of hippocampal
neurons with excitotoxic concentrations of glutamate (Brustovetsky
et al., 2010).
Increased calpain activity is a prominent feature of postmortem AD
brain (Nixon, 2003), leading to speculation that NCX function may be
altered during the development of AD. Application of Ab1–42 to primary
neuronal cultures results in the elevation of calpain-1 activity (Town
et al., 2002; Noble et al., 2009), and transgenic mice over-expressing
mutant human APP also exhibit increased calpain-1 activity (Vaisid et al.,
2007). Thus, it is possible that Ab-induced increases in calpain activity
may modulate NCX3 function in AD. In support of this, Sokolow et al.
(2011) demonstrated co-localization of NCX3 and Ab in synaptosome
preparations from AD brain and a loss of NCX3 holoprotein in
homogenates of parietal cortex in AD.
In this study, we have investigated the possibility that NCX3 function
is disrupted in AD as a result of NCX cleavage by calpain. Examination of
postmortem human brain showed that elevated calpain-1 activity and
reduced activity of the endogenous calpain inhibitor, calpastatin, are
closely associated with increased fragmentation of NCX3 in AD brain.
This appears to be relatively specific for AD as significantly altered NCX3
Correspondence
Wendy Noble, Institute of Psychiatry, Department of Neuroscience, King’s College
London, (PO37)DeCrespignyPark, LondonSE58AF,UK.Tel.:+44 (0)20 7848 0578;
fax: +44 (0)20 7708 0017; e-mail: Wendy.Noble@kcl.ac.uk
†These authors contributed equally to this work.
Accepted for publication 28 July 2013
ª 2013 the Anatomical Society and John Wiley & Sons Ltd 49
Aging Cell (2014) 13, pp49–59 Doi: 10.1111/acel.12148
Ag
in
g 
Ce
ll
cleavage was not observed in brain from other neurodegenerative
tauopathies. The other tauopathies examined were frontotemporal
dementia with parkinsonism associated with tau mutations on chromo-
some 17 (FTD), corticobasal degeneration (CBD) and progressive
supranuclear palsy (PSP). It is worth noting that CBD and PSP also show
significant tau pathology in the frontal cortex in end-stage disease,
especially when assessed using biochemical methods (Zhukareva et al.,
2006).
No changes were observed in either the total protein amounts or
cleavage of NCX1, another NCX family member, in any neurodegener-
ative tauopathy brain. This suggests that related proteins do not
compensate for NCX3 inactivation in AD. In addition, our data suggest
that the over-production of Ab in AD is likely to cause calpain-mediated
NCX3 cleavage, because we found a significant positive correlation
between Ab amounts and calpain-mediated NCX3 cleavage in AD brain.
In primary neural cell cultures, treatment with 10 lM Ab1–42 induced
calpain cleavage of NCX3, and this was prevented by treatment with the
calpain inhibitor, calpeptin. In addition, suppression of NCX3 expression
with antisense oligonucleotides sensitized neurons to normally subtoxic
concentrations of Ab1–42.
Results
NCX3 is cleaved by both calpain-1 and caspase-3 in cell models of
neurological disease (Bano et al., 2005). Thus, we first determined the
relative activities of these proteases in neurodegenerative disease brain
on Western blots. To determine whether any changes detected were
specific to AD, we also examined three other tauopathies, PSP, CBD and
FTD caused by the intronic tau mutation 10 + 16.
Calpain-1 activity is increased in tauopathy brain
Calpain-1 is an approximately 80-kDa Ca2+-activated cysteine protease
that is activated by its autolysis into 76- and 58-kDa fragments (Goll
et al., 2003). Blots of postmortem human brain were probed with an
antibody that specifically detects the active 76-kDa subunit of calpain-1
(Fig. S1, Supporting information), revealing a single prominent band of
the expected size (Fig. 1A). Blots were also probed with an antibody to
neuron-specific enolase (NSE) for normalization purposes and to control
for any loss of neuronal proteins and/or gliosis. This analysis revealed that
active calpain-1 is significantly increased in AD cortex (P < 0.001) when
compared to controls (Fig. 1B). In addition, significantly increased
amounts of active calpain-1 were also detected in cortex from PSP,
CBD and FTD brain (P < 0.05 for all). Blots were also probed with an
antibody against calpain-2 that detects calpain-2 holoprotein at 76–
80 kDa and active calpain-2 at 58 kDa (Huang et al., 2010). When
standardized against NSE, somewhat elevated amounts of active calpain-
2 were detected in AD and FTD brain; however, these differences were
not statistically significant (Fig. 1A,C). Nevertheless, these findings
confirm previous data showing that calpain-1 activity is increased in
AD brain (Saito et al., 1993) and indicate that increased calpain-1
cleavage to its active form is observed not only in conditions character-
ized by elevated Ab deposition, but also in a number of other
neurodegenerative tauopathies.
Active calpastatin is decreased in neurodegenerative
disease brain
An important cellular regulator of calpain activity in the brain is the
endogenous calpain-1 and calpain-2 inhibitor, calpastatin (CAST) (Rao
et al., 2008). It has been suggested that reduced CAST amounts and/or
activities might contribute to the increased activation of calpain observed
in AD brain (Rao et al., 2008). To examine CAST activity in tauopathy
brain, cortical lysates were immunoblotted with a polyclonal antibody
directed against human CAST. This antibody detects CAST holoprotein
at 110–120 kDa, as well as a number of calpain-cleaved CAST fragments
of 37–75 kDa, which, together with the full-length protein, have calpain
inhibitory activity. Several inactive CAST fragments (< 25 kDa), gener-
ated by the action of caspase-1 and caspase-3 on CAST (Rao et al.,
2008), were also detected by this antibody (Fig. 1A).
Following normalization to NSE, we found no differences in the total
amount (intact plus fragments) of CAST between any groups (Fig. 1D).
In contrast, there was a significant decrease in the amount of full-length
CAST as a proportion of total CAST in AD brain relative to controls
(P < 0.05, Fig. 1E), with samples from other tauopathies showing a
trend towards decreased CAST holoprotein. The amounts of active CAST
(holoprotein plus 37–75 kDa fragments) and inactive CAST (fragments
< 25 kDa) were then quantified as a proportion of total CAST. We found
significant decreases in the amounts of active CAST fragments and
corresponding increases in inactive CAST protein, in AD, PSP, CBD and
FTD in comparison with control brain (Fig. 1F,G). These findings support
previous results showing reduced CAST activity in AD brain (Nilsson
et al., 1990; Nixon, 2003; Rao et al., 2008) and extend this data with
the novel finding that CAST activity is decreased in brain from ‘pure’
tauopathies.
Active caspase-3 is not increased in postmortem
neurodegenerative disease brain
As caspase-3 can also cleave and inactivate NCX3 (Bano et al., 2007),
we next assessed the activity of this protease in the control and diseased
brain samples. Caspase-3 exists as a holoprotein (pro-caspase-3,
approximately 32 kDa) with limited enzymatic activity. Caspase-3 is
cleaved by caspase-8 and caspase-9 to generate active fragments of
approximately 17 and 19 kDa. Western blotting with an antibody that
detects active caspase-3 revealed a prominent band of 19 kDa and a
relatively weak band at 17 kDa, corresponding to active caspase-3
fragments (Fig. 1A). Relative to NSE, we found no significant increases in
the amounts of cleaved caspase-3 fragments in any of the neurode-
generative conditions investigated when compared to control brain
(Fig. 1H). This finding suggests that caspase-3 activity is not globally
increased in neurodegenerative disease cortex, at least not to an extent
detectable by immunoblotting. This is consistent with previous reports
showing that only ‘exceptional’ neurons label with antibodies against
active caspase-3 in AD brain (Jellinger & Stadelmann, 2000).
Altered proteolysis of the calpain and caspase-3 substrate,
a-spectrin, in neurodegenerative disease brain
To further assess calpain-1 and caspase-3 activities in neurodegenerative
disease brain, calpain-1- and caspase-3-mediated cleavage of the
cytoskeletal protein a-spectrin was examined. Calpains cleave 240 kDa
a-spectrin holoprotein to generate 145- and 150-kDa products, whereas
cleavage by caspase-3 results in the production of 120- and 150-kDa
fragments (Martin et al., 1995). When standardized to NSE, there were
no significant differences in total a-spectrin amounts (holoprotein and all
fragments) between groups (Fig. 2A,B). In contrast, when the amount of
full-length a-spectrin was quantified as a proportion of total a-spectrin,
analysis revealed a loss of the holoprotein in AD (P < 0.05) and CBD
(P < 0.005) brain (Fig. 2A,C). We also observed a significant increase in
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the amount of 140–50 kDa calpain- and caspase-cleaved fragments as a
proportion of total a-spectrin in AD (P < 0.01) brain when compared to
controls (Fig. 2A,D). In contrast, when the 110- to 125-kDa caspase-
cleaved a-spectrin products were analysed as a proportion of total
a-spectrin, a significant increase in the amount of these fragments was
found only in CBD brain (P < 0.01) (Fig. 2A,E). As there were no
significant increases in the amount of the caspase-3-cleaved 110- to
125-kDa fragments in AD brain, this suggests that the accumulation of
the 140- to 150-kDa fragments detected in these brains occurs as a result
of calpain, rather than caspase, activity. Therefore, these findings appear
to support the notion of increased calpain-mediated proteolysis in AD.
NCX3 cleavage by calpain is elevated in AD brain
We next determined the amount of full-length and cleaved NCX3 in
postmortem human brain. Western blotting with an antibody previously
(A)
(B)
(E)
(H)
(F) (G)
(C) (D)
Fig. 1 Calpain-1 active subunit amounts are elevated in neurodegenerative disease brain. (A) Representative immunoblots of cortical lysates from postmortem brain. Blots
were probed with antibodies that detect active fragments of calpain-1 at 76 kDa, calpain-2 holoprotein and cleaved fragments at 76 and 58 kDa, respectively, and active
caspase-3 at 17 and 19 kDa. An antibody against calpastatin (CAST) was used that detects active CAST holoprotein at 110 kDa, active fragments of > 25 kDa and inactive
fragments of < 25 kDa. Blots were also probed with an antibody- to neuron-specific enolase (NSE), 45 kDa. Box plots show amounts of (B) active calpain-1, (C) active
calpain-2 and (D) total CAST, all as a proportion of NSE. (E) Full length (FL) CAST, (F) active CAST and (G) inactive CAST, all as a proportion of total CAST, and (H) active
caspase-3 following standardization to NSE content in each sample. CTRL: control (n = 20), AD: Alzheimer’s disease (n = 20), PSP: progressive supranuclear palsy (n = 5),
CBD: corticobasal degeneration (n = 5), FTD: frontotemporal dementia with tau mutations (n = 4). *P < 0.05, **P < 0.005, ***P < 0.001.
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shown to detect full-length and cleaved NCX3 in cultured neurons (Bano
et al., 2005) revealed a band of approximately 110 kDa, which
corresponds to the predicted molecular weight of full-length NCX3
(Fig. 3A). In addition, a single band of approximately 66 kDa was
observed, which corresponds to caspase-cleaved NCX3, and a cluster of
bands of approximately 60 kDa are calpain-cleaved NCX3 (Bano et al.,
2005, 2007). Blots were normalized by probing with an antibody against
NSE.
Quantification of the total amount of NCX3 (intact plus fragmented)
showed that there were no significant differences between any
tauopathy and control brain following normalization to NSE (Fig. 3B).
There was, however, a significant decrease in the amount of NCX3
holoprotein in AD brain relative to control (Fig. 3C, P < 0.005) in
agreement with previous studies (Sokolow et al., 2011). This reduction
in intact NCX3 appeared to be specific to AD brain because full-length
NCX3 was not significantly altered in PSP, CBD or FTD brain. In addition,
no significant differences in the amount of caspase-3-cleaved NCX3
fragments were detected in any tauopathy tissue (Fig. 3D), supporting
our earlier findings that there is no global increase in caspase-3 activity in
these brains. However, we found a significant increase in the amount of
calpain-cleaved NCX3 in AD, but not in any other disease group, when
compared to control brain (Fig. 3E). This is consistent with our finding of
decreased intact NCX3 in these samples and our demonstration of
elevated calpain-1 activity in AD brain. It is possible that NCX3 cleavage
is increased in AD as a result of altered neuronal distribution of active
calpain and/or NCX3, as suggested by previous studies (Sokolow et al.,
2011). These results indicate that calpain-mediated cleavage of the
NCX3 exchanger is a prominent feature of AD brain. Because NCX3
cleavage disrupts the ion exchanger activity of this channel (Bano et al.,
2005, 2007), this finding suggests that altered NCX3 function may
contribute to the abnormal neuronal regulation of Ca2+ in AD.
We also assessed the amount of NCX1 in these brain samples to
determine whether there are alterations in the amounts or activity of this
related ion exchanger in neurodegenerative disease brain, which may
indicate compensation for loss of NCX3 function. When Western blots
were probed with an antibody that detects NCX1, an immunoreactive
band was observed at approximately 120 kDa, corresponding to the
predicted molecular weight of full-length NCX1 (Shaikh et al., 2010) as
well as cleaved species at 70–80 kDa (Fig. 3A). Quantification of total
NCX1 protein as a proportion of NSE revealed no significant alterations
in NCX1 in any of the neurodegenerative disease brains when compared
to controls. Moreover, no changes in the amount of full-length NCX1, or
calpain-cleaved NCX1 species, were detected in any experimental group
in relation to control brain (data not shown). These results indicate that
loss of NCX3 function does not result in an upregulation of the related
family member, NCX1.
Ab1-42 burden correlates with NCX3 cleavage in AD brain
Because Ab is known to activate calpain-1 in neurons, we sought to
determine whether increased calpain-mediated NCX3 cleavage is
associated with elevated Ab amounts in postmortem AD brain. Ab
ELISAs were used to determine total amounts of Ab1–40 and Ab1–42,
and the ratio of Ab1–42/Ab1–40 in control and AD brain (Fig. 4A–C).
These data were then correlated with the amounts of active calpain-1
proteins and calpain-cleaved NCX3 fragments (Fig. 4D–I). These analyses
revealed that Ab1–42 amounts significantly correlate with calpain
activity (Fig. 3E, P < 0.05) and the presence of calpain-cleaved NCX3
protein fragments (Fig. 3H, P < 0.005) in control and AD brain. We also
found a strong correlation between calpain-1 activity and the amounts
of calpain-cleaved NCX3 fragments, as would be expected (Fig. 4J).
These data support the hypothesis that calpain-mediated NCX3 cleavage
(A)
(B)
(E)
(C) (D)
Fig. 2 Calpain- and caspase-mediated
proteolysis of a-spectrin in
neurodegenerative disease brain. (A)
Representative immunoblot of cortical
lysates from postmortem brain. Blots were
probed with an antibody that detects a-
spectrin holoprotein at approximately
240 kDa, calpain- and caspase-cleaved
fragments at approximately 140–150 kDa
and caspase-cleaved fragments at
approximately 110–125 kDa. Blots were
also probed with an antibody to neuron-
specific enolase (NSE), 45 kDa. Box plots
show quantification of (B) total a-spectrin
following standardization to NSE amounts.
(C) a-spectrin holoprotein, (D) 140- to 150-
kDa a-spectrin fragments and (E) 110- to
125-kDa a-spectrin fragments, all
quantified as a proportion of total a-
spectrin. Mean  standard error is shown.
CTRL: control (n = 20), AD: Alzheimer’s
disease (n = 20), PSP: progressive
supranuclear palsy (n = 5), CBD:
corticobasal degeneration (n = 5), FTD:
frontotemporal dementia with tau
mutations (n = 4). *P < 0.05, **P < 0.005.
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is driven by altered Ab production in AD brain. Unfortunately, due to the
small number of samples available, it was not possible to correlate
calpain-1 activity and NCX3 cleavage in brain from other tauopathies.
Ab induces calpain-dependent NCX3 cleavage
To determine whether calpain-mediated cleavage of NCX3 is causally
related to elevated Ab amounts in AD, we measured NCX3 cleavage
following application of 10 lM soluble oligomeric Ab1–42 to primary
cortical neuronal cultures for 48 h. We have previously shown that this
treatment results in neurotoxicity (Noble et al., 2009; Garwood et al.,
2011). Western blots of cell lysates revealed increased amounts of active
calpain-1 (76 kDa) and caspase-3 (19 kDa) in neurons exposed to Ab
relative to vehicle-treated cells (Fig. 5A–C). Total NCX3 protein amounts
were unchanged by Ab treatment (Fig. 5A), although there was a small,
but nonsignificant reduction in the amount of full-length NCX3 present
in Ab-treated cells following standardization to b-actin amounts (data
not shown). In contrast, Ab treatment increased the generation of
calpain-cleaved (66 kDa) fragments of NCX3 (Fig. 5D, P < 0.05), and
this was prevented when neurons were pretreated for 3 h with the
calpain inhibitor, calpeptin (5 lM, Fig. 5A,D), which also lowered
Ab-induced increases in calpain activity (Fig. 5B). The generation of
caspase-cleaved NCX3 fragments were not affected by Ab treatment
(Fig. 5A,E). These findings show that Ab1–42 induces calpain-dependent
cleavage of NCX3 in primary cortical neurons, and therefore, elevated
Ab content may account for the increased NCX3 cleavage we observed
in AD brain relative to controls.
To determine whether calpain-mediated NCX3 cleavage is associated
with Ab-induced neurotoxicity, primary cortical cultures were pretreated
with 5 lM calpeptin prior to application of 10 lM soluble oligomeric Ab,
and cell death was assessed by live/dead assay (Fig. 5F) and LDH release
(Fig. 5G). Ab treatment for 48 h resulted in a statistically significant
increase in neuronal cell death, as observed by the degeneration of bIII-
tubulin-labelled primary neurons (green), increased incorporation of dead
cell dye (red) and the appearance of fragmented, condensed nuclei (blue).
The extent of cell death was reduced upon pretreatment of cultures with
calpeptin (Fig. 5F). These results were confirmed by the measurement of
lactate dehydrogenase (LDH) release (Fig. 5G). These findings show that
elevated calpain activity is closely associated with Ab-induced neurotox-
icity and suggest that Ab-induced calpain-mediated NCX3 cleavage may
contribute to neuronal loss in AD, perhaps by preventing the extrusion of
excess intraneuronal Ca2+.
NCX3 expression mediates Ab-induced neurotoxicity
To further investigate the role of NCX3 in Ab-mediated neurotoxicity, rat
primary cortical cultures were treated with phosphorothioated sense or
antisense oligonucleotides specific for rat NCX3, as previously described
(Iwamoto & Kita, 2006). Western blotting confirms that treatment of
cultured neurons with antisense NCX3 oligonucleotides for 24 h resulted
(A)
(B)
(E)
(C) (D)
Fig. 3 Calpain-mediated cleavage of
NCX3, but not NCX1, is increased in AD
brain. (A) Representative immunoblots of
cortical lysates from postmortem brain.
Blots were probed with an antibody that
detects NCX3 holoprotein at approximately
110 kDa, a caspase-3-cleaved fragment at
approximately 66 kDa, calpain-cleaved
fragments at approximately 60 kDa and an
antibody against NCX1, which detects full-
length NCX1 at 120 kDa and proteolytic
fragments at approximately 70–80 kDa.
Blots were also probed with an antibody to
neuron-specific enolase (NSE), 45 kDa.
Plots show quantification of (B) total NCX3
amounts when standardized to NSE, and
(C) full-length NCX3, (D) caspase-3-cleaved
NCX3 and (E) calpain-cleaved NCX3, all as a
proportion of total NCX3. CTRL: control
(n = 20), AD: Alzheimer’s disease (n = 20),
PSP: progressive supranuclear palsy (n = 5),
CBD: corticobasal degeneration (n = 5),
FTD: frontotemporal dementia with tau
mutations (n = 4). **P < 0.005.
Aberrant NCX3 cleavage in AD, J. Atherton et al. 53
ª 2013 the Anatomical Society and John Wiley & Sons Ltd
in an approximately 38.5  12.6% reduction in NCX3 protein amounts
(Fig. 6A), in line with previous observations in primary neurons (Ranciat-
McComb et al., 2000). The amounts of NCX3 fragments were less
affected by exposure to antisense oligonucleotides, suggesting that the
turnover rate of cleaved NCX3 may be slower than that of the full-length
protein. Sense oligonucleotides to NCX3 had no effect on NCX3 levels
(Fig. 6A). Cultures were also treated with 1 lM Ab for a further 16 h.
This treatment alone had no significant effect on cell death in
comparison with vehicle-treated cells (Fig. 6B). In contrast, application
of 1 lM Ab for 16 h caused a significant increase in cell death in cells
treated with antisense NCX3 oligonucleotides in comparison with cells
treated with vehicle or sense NCX3 oligonucleotides (P < 0.05, Fig. 6B).
The relatively modest extent of the enhanced sensitivity to Ab toxicity
may be indicative of compensation for NCX3 loss of function in these
cells, as has been previously demonstrated in rat cerebellar granule cells
(Bano et al., 2007). Nevertheless, these results indicate that reduced
expression of functional NCX3 exchangers can sensitize cultured neurons
to Ab.
(A) (B) (C)
(D) (E) (F)
(G) (H)
(J) (K)
(I)
Fig. 4 NCX3 cleavage correlates with calpain-1 activity and Ab burden. Ab ELISAs were used to measure Ab amounts in frontal cortex samples from AD and control (CTRL)
brain. Box plots show (A) Ab1–40, and (B) Ab1–42amounts in pg mL1, (C) shows the ratio of Ab1–42 to Ab1–40. Scatter plots show the correlation between amounts of
active calpain-1 and (D) Ab1–40, (E) Ab1–42 and (F) Ab1–42/Ab1–40, and between calpain-cleaved NCX3 fragments and (G) Ab1–40, (H) Ab1–42, (I) Ab1–42/Ab1–40, and
(J) active calpain-1, and (K) caspase-cleaved NCX-3 fragments with active caspase-3. Parametric Pearson correlation analysis was used to generate r values since all data were
normally distributed, and statistical statistical significance is shown for each analysis. CTRL: control (n = 16), AD: Alzheimer’s disease (n = 16).
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Discussion
Altered cellular Ca2+ homeostasis is an early and prominent feature of
AD that likely accelerates disease progression (Small, 2009). In cell
models of AD, Ab-induced neuronal Ca2+ influx through native ion
channels and/or plasma membrane pores leads to synaptic deficits,
altered long term potentiation, learning and memory impairments,
and neurotoxicity (Smith et al., 2005). Similarly, altered cellular Ca2+
regulation is apparent in the vicinity of amyloid plaques in transgenic
mice expressing mutant human APP (Kuchibhotla et al., 2008).
Many downstream effects of increased [Ca2+]i have been reported
that may modify the progression of AD, including Ca2+-dependent
activation of the calpain family of proteases. Calpains mediate an array
of disease-associated events including aberrant amyloid precursor
protein processing (Mathews et al., 2002), generation of potentially
toxic tau fragments (Nicholson et al., 2011), activation of key tau protein
kinases including cyclin-dependent kinase 5 and glycogen synthase
kinase 3 (Town et al., 2002; Goni-Oliver et al., 2007), processing of
dynamin 1, a protein critically involved in memory formation (Kelly et al.,
2005), Ab-induced synaptic dysfunction (Trinchese et al., 2008) and LTP
impairment (Li et al., 2011). These data thus suggest a key role for
calpains as mediators of the synaptotoxic and neurotoxic events that
occur downstream of Ab-induced increases in AD.
In addition, calpain activation has also been demonstrated to
influence the cellular mechanisms that regulate Ca2+ efflux. Several
studies have shown that calpain cleaves and inactivates NCX3 ion
exchangers, preventing the extrusion of excess neuronal Ca2+ (Bano
et al., 2005, 2007; Brustovetsky et al., 2010). Here, we have demon-
strated that Ab induces calpain-mediated NCX3 cleavage in primary
cortical cultures, suggesting that NCX3 cleavage may perhaps contribute
to sustained and neurotoxic increases in cellular Ca2+ in AD. In support
of this idea, we show that inhibition of calpain activity ameliorates
Ab-induced neuronal loss and that suppressing NCX3 expression with
antisense oligonucleotides sensitizes neurons to normally subtoxic doses
of Ab.
We also observe elevated calpain activity and NCX3 cleavage in
postmortem AD brain. Whilst the total amount of NCX3 protein is
unchanged, NCX3 truncation was associated with loss of NCX3
holoprotein, supporting previous findings of decreased full-length
NCX3, but not NCX1 or NCX2, in parietal cortex or synaptosome
preparations from a relatively small number of AD cases (Sokolow et al.,
2011). Moreover, the increased proteolysis of NCX3 that we observed
showed significant positive correlation with amounts of Ab1–42 in
frontal cortex. Because significantly increased NCX3 cleavage was
detected only in AD, but not other tauopathy brain, this raises the
possibility that analysis of NCX3 fragments may have utility as a
(A)
(B) (C)
(D) (E)
(F)
(G)
Fig. 5 Ab-induced calpain-mediated NCX3 cleavage is associated with neurotoxicity in primary cortical cultures. Rat primary cortical cultures were exposed to 10 lM Ab1–
42 (Ab) for 48 h with and without pretreatment with 5 lM calpeptin (CPTN) for 1 h. (A) Representative Western blots probed with antibodies against active calpain-1
(76 kDa) and that pick up full-length (110 kDa), caspase-cleaved (66 kDa) and calpain-cleaved (60 kDa) NCX3 are shown. Blots were also probed with b-actin (42 kDa) as a
loading control. Molecular weight markers are indicated (kDa). Bar charts show amounts of (B) active calpain-1 and (C) active caspase-3 as a proportion of b-actin in each
sample. The amounts of (D) calpain-cleaved and (E) caspase-cleaved NCX3, both as a proportion of total NCX3, are also shown. (F) Representative images from cortical
cultures incubated with live/dead cell dye (red), fixed and immunostained with an antibody against bIII-tubulin (green). Hoechst 33352 was used to stain nuclei (blue). Scale
bar: 25 lm. (G) Lactate dehydrogenase (LDH) release from control and treated primary cortical cultures. Values represent LDH release from cells into the medium as a
percentage of total LDH, presented as % control. Data are mean  SEM. Experiments were performed in triplicate (n = 3). *P < 0.05.
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biomarker for AD. It is of interest that increased abundance of NCX3
fragments was only observed in AD brain despite other tauopathies also
showing elevated calpain activity. It has previously been shown that tau
can bind to EF hand domain-containing proteins (Vega et al., 2008). It is
therefore possible that NCX3 fragments may bind PHF tau, a confor-
mation of tau that is found in AD and not other tauopathy brain, and
thereby become sequestered into insoluble tau aggregates that are not
easily degraded, thereby leading to an accumulation of these fragments
in postmortem AD brain. A similar mechanism may explain the increase
in calpain-cleaved a-spectrin fragments that were found to accumulate in
AD tissue. Indeed, cleaved a-spectrin fragments have previously been
identified in affected neurons in AD brain (Ayala-Grosso et al., 2006).
Accumulating evidence shows that Ab induces disruptions in cellular
Ca2+ homeostasis that are particularly detrimental to synaptic function in
AD (Wu et al., 2010). NCX3 is expressed in subpopulations of neurons,
where it localizes predominantly to dendrites and distal astrocyte
processes that contact excitatory synapses (Minelli et al., 2007). This
positioning suggests that NCX3 may play a key role in regulating Ca2+
currents during synaptic activity. Furthermore, NCX3 buffering of
astrocytic Na+ could further impact on synaptic function by regulating
the activity of Na+-dependent glutamate transporters that are critical for
the clearance of extracellular glutamate during synaptic activity (Minelli
et al., 2007). Because healthy synaptic transmission is essential for
normal learning and memory (DeKosky & Scheff, 1990; Sze et al., 1997),
this implies that NCX3-mediated sustained elevations in neuronal Ca2+
may contribute to the synaptic dysfunction and cognitive deficits
associated with Ab in AD. Indeed, NCX3 has been shown to play a
crucial role in regulating LTP, spatial learning and memory. Higher basal
[Ca2+]i, due to delayed Ca
2+ clearance after stimulation of neuronal
activity, impaired synaptic transmission and reduced performance in
spatial learning and memory tasks have all been observed in NCX3
knockout mice (Molinaro et al., 2011), a situation analogous to
proteolytic inactivation of NCX3. These findings suggest therefore that
targeting aberrant NCX3 cleavage by calpain may have therapeutic
potential for the treatment for Alzheimer’s disease.
Experimental procedures
Postmortem human brain
Frozen postmortem human frontal cortex (Table 1) from control brain
(N = 20) and pathologically confirmed cases of AD (N = 20), progressive
supranuclear palsy (PSP) (N = 5), corticobasal degeneration (CBD)
(N = 5) and frontotemporal dementia with parkinsonism associated
with tau mutations on chromosome 17 (FTD) (n = 4) were obtained
from the MRC London Brain Bank for Neurodegenerative Diseases, Kings
College London, Institute of Psychiatry. Frozen tissue was homogenized
(200 mg mL1) in ice-cold lysis buffer, 50 mM Tris-buffered saline,
0.1% (w/v) Triton X-100, 10 mM sodium fluoride, 1 mM sodium
orthovanadate, 2 mM ethylene glycol tetraacetic acid, 1 mM phenyl-
methylsulfonyl fluoride and CompleteTM protease inhibitor (Roche),
pH 7.4, using a mechanical homogenizer. Following centrifugation of
homogenates at 25 000 g(av) for 20 min at 4 °C, the supernatants
were collected, and protein concentrations were measured using a BCA
protein assay kit (Pierce Endogen, Rockford, IL, USA). Samples were
standardized to equal protein concentration before being analysed by
Western blotting.
Primary cortical cell culture
Primary cortical neuronal cultures were prepared from embryonic day
18 (E18) rat embryos as described previously (Pooler et al., 2013).
Cultures are primarily neuronal with approximately 4% astrocytes and
negligible numbers of oligodendrocytes and microglia (Garwood et al.,
2011). Cultures were treated with 10 lM soluble oligomeric Ab1–42
(California Peptide Co., Napa, CA, USA). To inhibit calpain activity, cells
were treated with 5 lM calpeptin (EMD Millipore, Billerica, MA, USA) or
vehicle for 24 h prior to addition of Ab. Ab1–42 was prepared according
to the method described in Garwood et al. (2011), which generates
predominantly soluble oligomeric species of Ab. After treatment, culture
medium was removed and cells were washed in phosphate-buffered
saline (PBS), lysed in ice-cold lysis buffer and centrifuged at 16 000 g(av)
for 20 min at 4 °C. The protein concentration of supernatants was
measured using a BCA protein assay kit, as described above, and protein
concentrations were standardized prior to analysis.
Treatment of primary cortical cultures with
oligodeoxynucleotides
Primary cortical cultures (4 DIV) were treated with antisense and sense
phosphorothioate oligodeoxynucleotides, specific for rat NCX3 (Iwam-
oto & Kita, 2006). The 5′–3′ sequences are as follows: NCX3 antisense:
GCCATACACAAGAG; NCX3 sense: CTCTTGTGTATGGC. Cells were
incubated with oligodeoxynucleotides (5 lM) and Lipofectamine 2000
(Invitrogen Life Technologies, Paisley, UK), according to the manufac-
turer’s protocol. Twenty-four hours after the application of oligonucle-
otides, neurons were treated with vehicle or subtoxic (1 lM)
concentrations of oligomeric Ab1–42 for a further 16 h.
(A)
(B)
Fig. 6 Antisense knockdown of NCX3 sensitizes cortical neurons to Ab. Rat
primary cortical cultures were treated with sense (s) or antisense (as)
oligonucleotides against rat NCX3 for 24 h and then treated with a subtoxic
concentration (1 lM) of Ab1–42 (Ab) for a further 16 h. (A) Representative
Western blots probed with antibodies that detect full-length (110 kDa) and
cleaved (66, 60 kDa) NCX3. Blots were also probed with b-actin (42 kDa) as a
loading control. Molecular weight markers are indicated. Bar charts show (A) total
NCX3 expression following standardization to the b-actin loading control and (B)
cell death as measured by live/dead cell assay in cells treated with 1 lM Ab as a
proportion of death in control cultures and antisense oligonucleotides 1 lM Ab
standardized to cells treated with sense NCX3 oligonucleotides only. Data are
mean  SEM (n = 3). *P < 0.05, **P < 0.005.
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Table 1 Characteristics of postmortem brain samples. Frontal cortex was obtained from postmortem control brains (CTRL), those with Braak stage IV–VI Alzheimer’s disease
(AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and frontotemporal dementia with parkinsonism associated with the 10 + 16 tau mutation on
chromosome 17 (FTD). Postmortem delay (PMD), age and sex were balanced between groups as far as possible
Diagnosis Case number Sex Age (years) PMD (h) Case notes
CTRL* A042/01 F 52 44 Carcinoma of the lung
CTRL* A278/96 F 77 29 Pulmonary embolism
CTRL* A239/95 F 79 38 Chronic obstructive airway disease
CTRL* A155/95 F 63 34 Myocardial infarction
CTRL* A094/95 F 80 31 Bronchopneumonia/liver failure
CTRL* A047/02 F 87 22 Carcinoma of the breast
CTRL* A170/00 F 68 9 Systemic lupus erythematosus
CTRL* A322/94 F 62 81 Haemothorax
CTRL* A346/95 M 85 16 Ruptured aortic aneurysm
CTRL* A135/95 M 65 24 Coronary artery occlusion
CTRL* A134/00 M 86 6 Myocardial infarction
CTRL* A401/97 M 85 42 Gastrointestinal haemorrhage
CTRL* A223/96 M 80 11 Carcinoma of the prostate
CTRL* A133/95 M 85 48 Left ventricular failure
CTRL* A149/01 M 95 44 Gastrointestinal bleed
CTRL A077/00 M 68 53 Ischaemic heart disease
CTRL A066/00 M 61 53 Cardiac arrest
CTRL* A330/94 M 69 52 Aortic aneurysm
CTRL A261/94 M 75 85 Unknown. Diabetic.
CTRL A320/94 M 77 96 Myocardial infarction
AD* A157/00 F 75 9 Braak stage IV
AD* A240/06 F 97 12 Braak stage V
AD* A010/06 F 67 56 Braak stage VI
AD* A210/05 F 84 18 Braak stage V
AD* A169/05 F 82 43 Braak stage V–VI
AD* A168/05 F 84 36 Braak stage V–VI
AD* A074/05 F 89 29 Braak stage V–VI
AD* A203/04 F 84 37 Braak stage V–VI
AD* A221/03 F 81 37 Braak stage V
AD* A188/00 F 64 10 Braak stage V
AD* A232/00 F 79 8 Braak stage V
AD* A074/06 F 69 25 Braak stage VI, diffuse
neocortical Lewy body disease
AD A309/07 F 83 7 Braak stage VI, mild
neocortical Lewy body disease
AD A219/07 F 82 5 Braak stage VI, mild amyloid angiopathy
AD* A206/07 M 81 47 Braak stage V
AD* A186/04 M 71 5 Braak stage V–VI
AD* A122/04 M 86 26 Braak stage V,
moderate amyloid angiopathy
AD* A176/01 M 71 41 Braak stage V–VI
AD A249/07 M 74 69 Braak stage V–VI
with amyloid angiopathy
AD A270/06 M 82 41 Braak stage VI with amyloid angiopathy
PSP A196/98 F 68 9
PSP A202/98 F 75 48
PSP A142/07 M 93 20
PSP A391/97 M 71 16
PSP A180/04 M 71 21
CBD A140/01 F 65 72
CBD A037/98 M 64 66
CBD A197/98 M 51 34
CBD A302/99 M 67 89
CBD A008/00 M 74 9
FTD A099/08 M 70 7 Tau mutation 10 + 16
FTD A171/02 M 71 5 Tau mutation 10 + 16
FTD A176/00 M 48 65 Tau mutation 10 + 16
FTD A074/00 M 67 35 Tau mutation 10 + 16
*Indicates samples from which tissue was available for the analysis of Ab content by ELISA (N = 16).
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Gel electrophoresis and Western blotting
Five to ten microgram protein was loaded onto 10% (w/v) SDS–
polyacrylamide gels. Separated proteins were blotted onto nitrocellulose
membranes (Whatman, Maidstone, UK) and blocked with 5% (w/v)
nonfat milk/0.05% (v/v) Tween 20 in PBS for 1 h. After blocking,
membranes were incubated overnight at 4 °C in blocking solution
containing primary antibody. Blots were washed and incubated with the
appropriate fluorophore-conjugated secondary antibodies for 1 h at
ambient temperature. Proteins were visualized and quantified using an
Odyssey Infrared Imaging system (Li-Cor Biosciences, Cambridge, UK).
Human postmortem brain samples were run on multiple gels, each of
which contained a standard control sample to enable comparison of
samples across gels. Statistical analysis was performed following
standardization of specific protein amounts in each sample against
NSE, used as a loading control. White lines separating lanes in some
immunoblots indicate removal of portions of the blots for clarity and/or
splicing together of distinct blots.
Antibodies
The following primary antibodies were used for Western blotting:
calpain-1 large active subunit (No. 2556, rabbit IgG; Cell Signalling Ltd,
Beverly, MA, USA); calpain-2 (AB81023, rabbit IgG; EMD Millipore, MA,
USA); calpastatin (CAST, #4146, rabbit IgG; Cell Signalling Ltd.); cleaved
(active) caspase-3 (Asp175, rabbit IgG; Cell Signaling Ltd.); neuron-
specific enolase (BBS/NC/VI-H14, mouse IgF; DAKO Ltd, Ely, UK); b-actin
(clone AC-15, mouse IgG; Abcam, Cambridge, UK). NCX3 and NCX1
antibodies were kindly provided by Professor Kenneth Phillipson (UCLA)
(Porzig et al., 1993; Thurneysen et al., 2002).
Cell death assays
Cytotoxicity was evaluated by measuring lactate dehydrogenase (LDH) in
culture medium using Cytotox 96 assay kits (Promega, Madison, WI,
USA) according to the manufacturer’s directions. After collection of
medium, the remaining cells were lysed in 0.9% (w/v) Triton X-100, and
LDH content in medium and lysed cells was measured to determine total
LDH content. Optical density was measured at 492 nm (Wallac 1420
Victor3 plate reader; Perkin-Elmer, Waltham, MA, USA). LDH release
from cells was calculated as a percentage of total LDH in each sample.
Cell death was confirmed using a live/dead fixable cell stain
(Invitrogen, Paisley, UK), performed according to the manufacturer’s
instructions. Following uptake of the amine-reactive fluorescent dye,
cells were washed, immunolabelled with an antibody against bIII-tubulin,
and nuclei were labelled with 1 lg mL1 Hoechst-33342 as described
previously (Garwood et al., 2011).
Ab1–40 and Ab1–42 ELISA
Ab1–40 and Ab1–42 in human brain samples were quantified using
ELISA kits from Invitrogen (Ab40 ELISA KHB3481; Ab1–42 ELISA
KHB3442) as we have previously described (Vagnoni et al., 2012).
Statistical analysis
Normalcy of data was first established using D’Agostino and Pearson
omnibus normality tests and was then analysed by parametric one-way
analysis of variance followed by Newman–Keuls post hoc tests
(Graphpad Prism v5.0; La Jolla, CA, USA). Differences were considered
statistically significant when P < 0.05. Differences in the amount of Ab
in control and AD human brain were assessed using two-tailed student t-
tests. These data were correlated with active calpain-1- and calpain-
cleaved NCX3 protein amounts using parametric two-tailed Pearson
tests.
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